Trial Profile
A Randomised, Double-Blind, Parallel-Group, Active-Controlled, Flexible Dose Study Exploring the Efficacy and Safety of 12 Weeks Treatment With Lu 31-130 in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Zicronapine (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- 20 Nov 2009 Status changed from active, no longer recruiting to completedNas reported by ClinicalTrials.gov.
- 30 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Oct 2009 Actual patient number (93) added as reported by ClinicalTrials.gov.